glp 1 drugs and parkinson's disease Glucagon-like peptide-1

GLP-1 Agonists: A New Frontier in Parkinson’s Treatment?

29.13

★★★★☆4.8 (126)

Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?

24.74

★★★★★4.9 (98)

GLP-1 receptor agonists (GLP-1RAs) are generating substantial interest in neurology due to preclinical neuroprotective effects and emerging — though mixed — clinical trial data across several

21.88

★★★★★5.0 (157)

Why are DPP-4 (Dipeptidyl Peptidase-4) inhibitors not typically combined with GLP-1 (Glucagon-Like Peptide-1) receptor agonists in patients with type 2 diabetes?

26.39

★★★★★4.7 (84)

GLP-1 receptor agonists should not be combined with DPP-4 inhibitors, as there is no added glucose-lowering benefit beyond that of the GLP-1 RA alone. Both drug classes work through overlapping mechanisms involving

22.34

★★★★★4.9 (203)

SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study

21.34

★★★★★5.0 (176)

GLP-1 receptor agonists should not be combined with DPP-4 inhibitors, as there is no added glucose-lowering benefit beyond that of the GLP-1 RA alone. Both drug classes work through overlapping mechanisms involving

29.30

★★★★★4.8 (132)